| 臺大學術典藏 |
2020-03-07T06:56:18Z |
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
|
Wu S-G.; Liu Y.-N.; Tsai M.-F.; YIH-LEONG CHANG; Yu C.-J.; Yang P.-C.; Yang J.C.-H.; Wen Y.-F.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-07T06:56:12Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; YIH-LEONG CHANG; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Yih-Leong Chang;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-07T06:56:09Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Yih-Leong Chang;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; YIH-LEONG CHANG; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-06T05:26:17Z |
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations
|
Chen Y.-F.; Hsieh M.-S.; Wu S.-G.; YIH-LEONG CHANG; Shih J.-Y.; Liu Y.-N.; Tsai M.-F.; Tsai T.-H.; Yu C.-J.; Yang J.C.-H.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:09Z |
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
|
Wu S-G.; Liu Y.-N.; Tsai M.-F.; YIH-LEONG CHANG; Yu C.-J.; Yang P.-C.; Yang J.C.-H.; Wen Y.-F.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-06T05:26:03Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; YIH-LEONG CHANG; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-06T05:26:00Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; YIH-LEONG CHANG; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-05T08:04:11Z |
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations
|
Chen Y.-F.; MIN-SHU HSIEH; Wu S.-G.; Chang Y.-L.; Shih J.-Y.; Liu Y.-N.; Tsai M.-F.; Tsai T.-H.; Yu C.-J.; Yang J.C.-H.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-05T08:04:09Z |
Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion
|
Tsai T.-H.; Wu S.-G.; MIN-SHU HSIEH; Yu C.-J.; Yang J.C.H.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-05T08:04:08Z |
Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations
|
Chen Y.-F.; MIN-SHU HSIEH; Wu S.-G.; Chang Y.-L.; Yu C.-J.; Yang J.C.-H.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-05T08:04:01Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; MIN-SHU HSIEH; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Min-Shu Hsieh;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-02-20T02:57:03Z |
Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy
|
Yu C.-J.; Yang J.C.H.; Yang P.-C.; Shih J.-Y.; Ruan S.-Y.; Wang J.-Y.; Chen K.-Y.; Jan I.-S.; Tsai T.-H.; CHING-YAO YANG; Ho C.-C.; Liao W.-Y. |
| 臺大學術典藏 |
2020-02-06T05:21:56Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Lai M.-S.;Yang J.C.H.;Cheng A.-L.;WEN-FANG CHENG;Hsu C.;Shao Y.-Y.;Yang Y.-Y.;Lai C.-L.;Shau W.-Y.;Kuo R.;Lin Z.-Z.;Kuo H.-Y.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; WEN-FANG CHENG; Cheng A.-L.; Yang J.C.H.; Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; WEN-FANG CHENG; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Kuo S.-H.; Cheng A.-L; Yang J.C.-H; Lu S.-H; Lin Z.-Z; Yu C.-J; Yang W.-C; Feng-Ming Hsu; Chen Y.-H; Shih J.-Y |
| 臺大學術典藏 |
2020 |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; WEI-YU LIAO; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020 |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yu C.-J.; Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tzu-Hsiu Tsai;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; TZU-HSIU TSAI; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H. |
| 臺大學術典藏 |
2020 |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Su K.-Y.; Chang Y.-L.; Liu Y.-N.; Hsu C.-L.; TZU-HSIU TSAI; Chen K.-Y.; Ho C.-C.; Liao W.-Y.; Yang C.-Y.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020 |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Yang C.-Y.; Yu C.-J.; Yang J.C.-H.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Chong-Jen Yu;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Kuo S.-H.; Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; CHONG-JEN YU; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2020 |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Chong-Jen Yu; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU |
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Kuo S.-H.; Cheng A.-L.; Yang J.C.-H.; Lu S.-H.; Lin Z.-Z.; Yu C.-J.; JIN-YUAN SHIH; Chen Y.-H.; Hsu F.-M.; Yang W.-C.; Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Jin-Yuan Shih;Yu C.-J.;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Kuo S.-H. |
| 臺大學術典藏 |
2020 |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; CHIA-LIN HSU; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 國立成功大學 |
2020 |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|
Sequist, L.V.;Han, J.-Y.;Ahn, M.-J.;Cho, B.C.;Yu, H.;Kim, S.-W.;Yang, J.C.-H.;Lee, J.S.;Su, W.-C.;Kowalski, D.;Orlov, S.;Cantarini, M.;Verheijen, R.B.;Mellemgaard, A.;Ottesen, L.;Frewer, P.;Ou, X.;Oxnard, G. |
| 國立成功大學 |
2020 |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de, Bono J.;Lin, C.-C.;Chen, L.-T.;Corral, J.;Michalarea, V.;Rihawi, K.;Ong, M.;Lee, J.-H.;Hsu, C.-H.;Yang, J.C.-H.;Shiah, H.-S.;Yen, C.-J.;Anthoney, Anthoney A.;Jove, M.;Buschke, S.;Fuertig, R.;Schmid, U.;Goeldner, R.-G.;Strelkowa, N.;Huang, D.C.-L.;Bogenrieder, T.;Twelves, C.;Cheng, A.-L. |
| 國立成功大學 |
2020 |
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial
|
Yang, J.C.-H.;Camidge, D.R.;Yang, C.-T.;Zhou, J.;Guo, R.;Chiu, Chiu C.-H.;Chang, G.-C.;Shiah, H.-S.;Chen, Y.;Wang, C.-C.;Berz, D.;Su, W.-C.;Yang, N.;Wang, Z.;Fang, J.;Chen, J.;Nikolinakos, P.;Lu, Y.;Pan, H.;Maniam, A.;Bazhenova, L.;Shirai, K.;Jahanzeb, M.;Willis, M.;Masood, N.;Chowhan, N.;Hsia, T.-C.;Jian, H.;Lu, S. |
| 臺大學術典藏 |
2019 |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Yang J.C.-H.; Tsai T.-H.; Chen K.-Y.; Yu C.-J.; Shih J.-Y.; WEI-YU LIAO; Lee J.-H.;Chen H.-Y.;Hsu F.-M.;Chen J.-S.;Wei-Yu Liao;Shih J.-Y.;Yu C.-J.;Chen K.-Y.;Tsai T.-H.;Yang J.C.-H.; Lee J.-H.; Chen H.-Y.; Hsu F.-M.; Chen J.-S. |
| 臺大學術典藏 |
2019 |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; JIN-YUAN SHIH; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Jin-Yuan Shih;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J.; Yu C.-J.; Yang J.C.-H.; Lin C.-C.; Chen J.-S.; Lin Z.-Z. |
| 臺大學術典藏 |
2019 |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yu C.-J.; Yang J.C.-H.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Shih J.-Y.; Chen K.-Y.; Ho C.-C.; WEI-YU LIAO; Yao Z.-H.; Yao Z.-H.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J. |
| 臺大學術典藏 |
2019 |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Yang J.C.-H.; Tsai T.-H.; Chen K.-Y.; Lee J.-H.; Chen H.-Y.; Hsu F.-M.; Chen J.-S.; Liao W.-Y.; Shih J.-Y.; CHONG-JEN YU; Lee J.-H.;Chen H.-Y.;Hsu F.-M.;Chen J.-S.;Liao W.-Y.;Shih J.-Y.;Chong-Jen Yu;Chen K.-Y.;Tsai T.-H.;Yang J.C.-H. |
| 臺大學術典藏 |
2019 |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Yang J.C.-H.; Tsai T.-H.; Chen K.-Y.; Yu C.-J.; Lee J.-H.; Chen H.-Y.; Hsu F.-M.; Chen J.-S.; Liao W.-Y.; JIN-YUAN SHIH; Lee J.-H.;Chen H.-Y.;Hsu F.-M.;Chen J.-S.;Liao W.-Y.;Jin-Yuan Shih;Yu C.-J.;Chen K.-Y.;Tsai T.-H.;Yang J.C.-H. |
| 國立成功大學 |
2019 |
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
|
Yang, J.C.-H.;Gadgeel, S.M.;Sequist, L.V.;Wu, C.-L.;Papadimitrakopoulou, V.A.;Su, W.-C.;Fiore, J.;Saraf, Saraf S.;Raftopoulos, H.;Patnaik, A. |
| 臺大學術典藏 |
2018-09-10T18:02:31Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Lee, C.K. ; Davies, L. ; Wu, Y.-L. ; Mitsudomi, T. ; Inoue, A. ; Rosell, R. ; Zhou, C. ; Nakagawa, K. ; Thongprasert, S. ; Fukuoka, M. ; Lord, S. ; Marschner, I. ; Tu, Y.-K. ; Gralla, R.J. ; Gebski, V. ; Mok, T. ; Yang, J.C.-H.; YU-KANG TU |
| 臺大學術典藏 |
2018 |
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Yang W.-C.;Fu-Ren Xiao;Shih J.-Y.;Ho C.-C.;Chen Y.-F.;Tseng H.-M.;Chen K.-Y.;Liao W.-Y.;Yu C.-J.;Yang J.C.-H.;Kuo S.-H.;Cheng J.C.-H.;Yang P.-C.;Hsu F.-M.; Yang W.-C.; FU-REN XIAO; Shih J.-Y.; Ho C.-C.; Chen Y.-F.; Tseng H.-M.; Chen K.-Y.; Liao W.-Y.; Yu C.-J.; Yang J.C.-H.; Kuo S.-H.; Cheng J.C.-H.; Yang P.-C.; Hsu F.-M. |
| 臺大學術典藏 |
2018 |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Yang J.C.-H.; Thress K.S.; Huang D.D.-R.; Bai Y.-Y.; Chang Y.-L.; Hsieh M.-S.; Su K.-Y.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Wei-Yu Liao;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; WEI-YU LIAO; Lee J.-H.; Tsai T.-H. |
| 臺大學術典藏 |
2018 |
Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion
|
Shih J.-Y.; Yang J.C.-H.; Yu C.-J.; Liu Y.-N.; SHANG-GIN WU; Shang-Gin Wu;Liu Y.-N.;Yu C.-J.;Yang J.C.-H.;Shih J.-Y. |
| 國立成功大學 |
2018 |
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
|
Wu, Y.-L.;Zhang, L.;Kim, D.-W.;Liu, X.;Lee, D.H.;Yang, J.C.-H.;Ahn, M.-J.;Vansteenkiste, J.F.;Su, W.-C.;Felip, E.;Chia, V.;Glaser, S.;Pultar, Pultar P.;Zhao, S.;Peng, B.;Akimov, M.;Tan, D.S.W. |
| 臺大學術典藏 |
2017 |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yu C.-J.; Yang J.C.H.; Lin C.-C.; Lin Z.-Z.; Chen J.-S.; JIN-YUAN SHIH; Chen K.-Y.; Ho C.-C.; Liao W.-Y.; Yao Z.-H.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Jin-Yuan Shih;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J. |
| 臺大學術典藏 |
2017 |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small-cell Lung Cancer
|
Lin Y.-T.;Liu Y.-N.;Wu S.-G.;Yang J.C.-H.;Jin-Yuan Shih; Lin Y.-T.; Liu Y.-N.; Wu S.-G.; Yang J.C.-H.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2017 |
Targeting RET in patients with RET-rearranged lung cancers: Results from the global, multicenter RET registry
|
Gautschi O.;Milia J.;Filleron T.;Wolf J.;Carbone D.P.;Owen D.;Camidge R.;Narayanan V.;Doebele R.C.;Besse B.;Remon-Masip J.;Janne P.A.;Awad M.M.;Peled N.;Byoung C.-C.;Karp D.D.;Van Den Heuvel M.;Wakelee H.A.;Neal J.W.;Mok T.S.K.;Yang J.C.H.;Ou S.-H.I.;Pall G.;Froesch P.;Zalcman G.;Gandara D.R.;Riess J.W.;Velcheti V.;Zeidler K.;Diebold J.;Fr?H M.;Michels S.;Monnet I.;Popat S.;Rosell R.;Karachaliou N.;Rothschild S.I.;Jin-Yuan Shih;Warth A.;Muley T.;Cabillic F.;Mazi?Res J.;Drilon A.; Michels S.; Monnet I.; Popat S.; Rosell R.; Karachaliou N.; Rothschild S.I.; JIN-YUAN SHIH; Warth A.; Muley T.; Cabillic F.; Mazi?res J.; Drilon A.; Gautschi O.; Milia J.; Filleron T.; Wolf J.; Carbone D.P.; Owen D.; Camidge R.; Narayanan V.; Doebele R.C.; Besse B.; Remon-Masip J.; Janne P.A.; Awad M.M.; Peled N.; Byoung C.-C.; Karp D.D.; Van Den Heuvel M.; Wakelee H.A.; Neal J.W.; Mok T.S.K.; Yang J.C.H.; Ou S.-H.I.; Pall G.; Froesch P.; Zalcman G.; Gandara D.R.; Riess J.W.; Velcheti V.; Zeidler K.; Diebold J.; Fr?h M. |
| 臺大學術典藏 |
2017 |
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component
|
J?nne P.A.;Ghiorghiu S;Cantarini M;Mann H;Chia-Chi Lin;Hirashima T;Gold K;Novello S;Yoh K;Haggstrom D;Blackhall F;Felip E;Planchard D;Kim J.-H;Kim S.-W;Su W.-C;Sequist L.V;Ramalingam S.S;Kim D.-W;Ahn M.-J;Yang J.C.-H; Yang J.C.-H; Ahn M.-J; Kim D.-W; Ramalingam S.S; Sequist L.V; Su W.-C; Kim S.-W; Kim J.-H; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Chia-Chi Lin; Mann H; Cantarini M; Ghiorghiu S; J?nne P.A. |
| 國立成功大學 |
2017 |
Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial
|
Thress, K.S.;Jacobs, V.;Angell, H.K.;Yang, J.C.-H.;Sequist, L.V.;Blackhall, F.;Su, W.-C.;Schuler, M.;Wolf, J.;Gold, K.A.;Cantarini, M.;Barrett, J.C.;J�nne, P.A. |
| 國立成功大學 |
2017 |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
|
Ahn, M.-J.;Kim, D.-W.;Cho, B.C.;Kim, S.-W.;Lee, J.S.;Ahn, J.-S.;Kim, T.M.;Lin, C.-C.;Kim, H.R.;John, T.;Kao, S.;Goldman, J.W.;Su, W.-C.;Natale, R.;Rabbie, S.;Harrop, B.;Overend, P.;Yang, Z.;Yang, J.C.-H. |
| 國立成功大學 |
2017 |
Genetic modifiers of progression-free survival in never-smoking lung adenocarcinoma patients treated with first-line tyrosine kinase inhibitors
|
Chang, I.-S.;Jiang, S.S.;Yang, J.C.-H.;Su, W.-C.;Chien, L.-H.;Hsiao, C.-F.;Lee, J.-H.;Chen, Chen C.-Y.;Chen, Chen C.-H.;Chang, G.-C.;Wang, Z.;Lo, F.-Y.;Chen, K.-Y.;Wang, Wang W.-C.;Chen, Y.-M.;Huang, M.-S.;Tsai, Y.-H.;Su, Y.-C.;Hsieh, W.-S.;Shih, W.-C.;Shieh, Shieh S.-H.;Yang, T.-Y.;Lan, Q.;Rothman, N.;Chen, Chen C.-J.;Chanock, S.J.;Yang, P.-C.;Hsiung, C.A. |
| 國立成功大學 |
2016-12 |
Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors or lymphoma
|
Lin, C. C.; Su, W. C.; Chao, Y.; Lee, J. H.; Hsu, C. H.; Cheng, A. L.; Chung, W. P.; Chen, M. H.; Lin, C. L.; Ho, H. L.; Huang, L. P.; Huang, C. T.; Hsueh, S. P.; Yang, J. C. H. |
| 國立臺灣大學 |
2016 |
Time to response in patients with ALK plus NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies
|
Gandhi, L.; Gadgeel, S.; Shaw, A.; Barlesi, F.; Crino, L.; Yang, J. C-H.; Dingemans, A-M. C.; Kim, D-W.; de Marinis, F.; Schulz, M.; Liu, S.; Fish, S.; Kotb, A.; Ou, S-H. I.; 楊志新 |
| 國立臺灣大學 |
2016 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
|
Schuler, M.; Yang, J. C. -H.; Park, K.; Kim, J. -H.; Bennouna, J.; Chen, Y. -M.; Chouaid, C.; De Marinis, F.; Feng, J. -F.; Grossi, F.; Kim, D. -W.; Liu, X.; Lu, S.; Strausz, J.; Vinnyk, Y.; Wiewrodt, R.; Zhou, C.; Wang, B.; Chand, V. K.; Planchard, D.; 楊志新 |
| 臺大學術典藏 |
2016 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
|
Schuler, M.;Yang, J. C. -H.;Park, K.;Kim, J. -H.;Bennouna, J.;Chen, Y. -M.;Chouaid, C.;De Marinis, F.;Feng, J. -F.;Grossi, F.;Kim, D. -W.;Liu, X.;Lu, S.;Strausz, J.;Vinnyk, Y.;Wiewrodt, R.;Zhou, C.;Wang, B.;Chand, V. K.;Planchard, D.; 楊志新; Schuler, M.; Yang, J. C. -H.; Park, K.; Kim, J. -H.; Bennouna, J.; Chen, Y. -M.; Chouaid, C.; De Marinis, F.; Feng, J. -F.; Grossi, F.; Kim, D. -W.; Liu, X.; Lu, S.; Strausz, J.; Vinnyk, Y.; Wiewrodt, R.; Zhou, C.; Wang, B.; Chand, V. K.; Planchard, D. |
| 臺大學術典藏 |
2016 |
Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations
|
Chen Y.-F.; Hsieh M.-S.; Wu S.-G.; YIH-LEONG CHANG; Yu C.-J.; Yang J.C.-H.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2016 |
Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer
|
Chen K.-Y.; Ho C.-C.; Yang J.C.-H.; CHIA-HSIEN CHENG; Hsu F.-M.; Lu S.-L.; Lu S.-L.;Hsu F.-M.;Chen K.-Y.;Ho C.-C.;Yang J.C.-H.;Chia-Hsien Cheng |
| 臺大學術典藏 |
2016 |
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
|
Yu C.-J.; Yang P.-C.; Yang J.C.-H.; Wen Y.-F.; JIN-YUAN SHIH; Chang Y.-L.; Tsai M.-F.; Wu S-G.;Liu Y.-N.;Tsai M.-F.;Chang Y.-L.;Yu C.-J.;Yang P.-C.;Yang J.C.-H.;Wen Y.-F.;Jin-Yuan Shih; Wu S-G.; Liu Y.-N. |
